by The ebola vaccine market has grown exponentially over the past decade owing to high prevalence of ebola virus disease across regions of Africa. Ebola vaccines provide effective immunization against the deadly viral hemorrhagic fever caused by Ebola virus. The demand for ebola vaccines is driven by their ability to prepare the immune system against ebolaviruses that cause Ebola virus disease.
The Global Ebola Vaccine Market is estimated to be valued at Us$ 6.72 Bn in 2024 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2024 To 2030.
Key Takeaways
Key players operating in the Ebola Vaccine Market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. These players are focused on developing more advanced and effective ebola vaccines to meet the growing demand. The growing prevalence of Ebola virus disease across African countries is fueling the demand for ebola vaccines globally. Various organizations are also taking initiatives to expand access to ebola vaccination in endemic regions, thereby driving the market growth. The increasing investments by market players as well as government and non-government organizations to conduct clinical trials and ramp up production capacity will support global expansion of the ebola vaccine market during the forecast period.
Market Key Trends
One of the major trends gaining traction in the ebola vaccine market is the growing adoption of recombinant vector vaccine technology. Unlike first-generation vaccines such as Zmapp, recombinant vector vaccines do not use actual virus components. They utilize another recombined but harmless virus to carry genes from ebolavirus and trigger an immune response. Several market players are developing recombinant vector ebola vaccines which are more stable and provide long-lasting immunity. Their ability to be stockpiled and need for only one dose is boosting product demand. This trends is expected to continue and drive the ebola vaccine market growth over the coming years.
Porter’s Analysis
Threat of new entrants: High capital requirements for production of ebola vaccines limits threat of new entrants.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of few alternatives.
Bargaining power of suppliers: Suppliers have high bargaining power as production requires specialized expertise and equipment.
Threat of new substitutes: Low threat of substitutes as ebola vaccines have few alternatives for prevention of deadly Ebola virus.
Competitive rivalry: Intense competitive rivalry exists among established players to gain more market share.
Geographical Regions
North America accounts for majority share in ebola vaccine market in terms of value owing to high healthcare expenditure and rapid adoption of new vaccines.
Asia Pacific shows fastest growth for ebola vaccine market driven by improving healthcare infrastructure, rising medical tourism, increased government funding for vaccine development in countries like China and India.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
